Get started
Author

Damon Willems

Observed names: D Willems, D. Willems, Willems, Damon
ORCID: 0000-0001-8263-4047
Observed ORCID: 0000-0001-8263-4047
OpenAlex ID: A5019982183
Burden of Hidradenitis Suppurativa: A Systematic Literature Review of Patient Reported Outcomes
2024 · Alexa B. Kimball, Joslyn Kirby, et al. · Dermatology and Therapy · 64
PDF
The importance of understanding patient and physician preferences for psoriasis treatment characteristics: a systematic review of discrete-choice experiments
2020 · Noem Sain, Damon Willems, et al. · Current Medical Research and Opinion · 42
Cost-effectiveness of romosozumab for the treatment of postmenopausal women with severe osteoporosis at high risk of fracture in Sweden
2021 · E. Söreskog, I. Lindberg, et al. · Osteoporosis International · 39
PDF
Identifying Unmet Care Needs and Important Treatment Attributes in the Management of Hidradenitis Suppurativa: A Qualitative Interview Study
2021 · Damon Willems, Mickael Hiligsmann, et al. · Patient · 29
PDF
Economic evaluation of a JAK inhibitor compared to a monoclonal antibody for treatment of moderate-to-severe atopic dermatitis from a UK perspective
2022 · Katja C. Heinz, Damon Willems, et al. · Journal of Medical Economics · 21
PDF
Patient Preferences in the Management of Hidradenitis Suppurativa: Results of a Multinational Discrete Choice Experiment in Europe
2023 · Damon Willems, Eva-Lotta Hinzpeter, et al. · Patient · 20
PDF
Comparative efficacy and safety of bimekizumab in axial spondyloarthritis: a systematic literature review and network meta-analysis
2023 · Atul Deodhar, Pedro M Machado, et al. · Rheumatology · 19
PDF
Comparative efficacy and safety of bimekizumab in psoriatic arthritis: a systematic literature review and network meta-analysis
2024 · Philip J Mease, Dafna D Gladman, et al. · Rheumatology · 18
PDF
Work productivity in patients with axial spondyloarthritis initiating biological or targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review and meta-analysis
2023 · Martin Rudwaleit, Michael F Mørup, et al. · RMD Open · 18
PDF
Cost-effectiveness of romosozumab for the treatment of postmenopausal women with osteoporosis at high risk of fracture in Belgium
2024 · Evelien Gielen, Martina Aldvén, et al. · Osteoporosis International · 17
PDF
Cost-Effectiveness of Emerging Treatments for Atopic Dermatitis: A Systematic Review
2023 · Katja C. Heinz, Charlotte Beaudart, et al. · PharmacoEconomics · 17
PDF
Cost-effectiveness intervention thresholds for romosozumab and teriparatide in the treatment of osteoporosis in the UK
2024 · Fredrik Borgström, Mattias Lorentzon, et al. · Osteoporosis International · 15
Improvement in work productivity among psoriatic arthritis patients treated with biologic or targeted synthetic drugs: a systematic literature review and meta-analysis
2024 · Laure Gossec, Brittany Humphries, et al. · Arthritis Research & Therapy · 15
PDF
Importance of Time Point–Specific Indirect Treatment Comparisons of Osteoporosis Treatments: A Systematic Literature Review and Network Meta-Analyses
2022 · Damon Willems, Muhammad Kassim Javaid, et al. · Clinical Therapeutics · 15
Cost-effectiveness of romosozumab for the treatment of postmenopausal women at very high risk of fracture in Canada
2022 · Ron Goeree, Natasha Burke, et al. · Archives of Osteoporosis · 14
PDF
A novel economic framework to assess the cost-effectiveness of bone-forming agents in the prevention of fractures in patients with osteoporosis
2021 · E. Söreskog, F. Borgström, et al. · Osteoporosis International · 14
PDF
A discrete-choice experiment to elicit the treatment preferences of patients with hidradenitis suppurativa in the United States
2023 · D. Willems, C. J. Sayed, et al. · Journal of Medical Economics · 11
PDF
Matching-Adjusted Indirect Comparison of the 52-Week Efficacy of Bimekizumab Versus Secukinumab and Ixekizumab for the Treatment of Radiographic Axial Spondyloarthritis
2024 · Walter P. Maksymowych, Howard Thom, et al. · Rheumatology and Therapy · 9
Comparative Effectiveness of Bimekizumab and Secukinumab in Patients with Psoriatic Arthritis at 52 Weeks Using a Matching-Adjusted Indirect Comparison
2024 · Philip J. Mease, Richard B. Warren, et al. · Rheumatology and Therapy · 9
PDF
Early health economic modelling for a treatment candidate in hidradenitis suppurativa
2020 · Damon Willems, Mata Charokopou, et al. · Journal of Medical Economics · 7
Comparative Effectiveness of Bimekizumab and Risankizumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect Comparison
2024 · Philip J. Mease, Richard B. Warren, et al. · Rheumatology and Therapy · 5
PDF
Treatment Preference Research in Atopic Dermatitis: A Systematic Review of Quantitative Studies
2024 · Katja C. Heinz, Charlotte Beaudart, et al. · Patient · 5
Comparative Effectiveness of Bimekizumab and Guselkumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect Comparison
2024 · Richard B. Warren, Iain B. McInnes, et al. · Rheumatology and Therapy · 5
PDF
Cost-effectiveness analysis of bimekizumab for the treatment of active psoriatic arthritis in Sweden
2023 · Valgerdur Sigurdardottir, Anna Engstrom, et al. · Journal of Medical Economics · 4
PDF
SA64 Comparative Effectiveness of Bimekizumab in Patients with Psoriatic Arthritis: Results from a Systematic Literature Review and Network Meta-Analysis
2023 · P.J Mease, D.D. Gladman, et al. · Value in Health · 3
PDF
Works count: 70
Citation count: 447
H-index: 14
I10-index: 17
Year
Topic
Type